AGC Biologics, a prominent global biopharmaceutical contract development and manufacturing organization (CDMO), has unveiled the expansion of its Longmont, Colorado facility with the addition of three state-of-the-art Grade B cell therapy manufacturing facilities. This strategic move is aimed at significantly increasing AGC Biologics' production capacity and bolstering its capabilities in the gene and cell therapy sector.

The expansion encompasses the integration of two new "process suites" and one "flex suite," adding over 30,000 square feet to the Longmont facility. The new space includes multiple isolation rooms, catering to a diverse range of products. The cleanroom boasts a cutting-edge modular design, featuring adaptable capacity configurations. Furthermore, the advanced cell therapy manufacturing facility supports both open and closed processes, catering to the production of autologous and allogeneic cell therapies.

This expansion establishes AGC Biologics Longmont as a comprehensive hub for gene and cell therapy services in North America. By offering a unified location for end-to-end development and manufacturing services, the company aims to provide developers with a seamless and efficient pathway to bring their products to market. The newly added cell therapy manufacturing facilities are set to complement the existing in-house viral vector development and manufacturing services, offering developers a comprehensive suite of services under one roof.

Whitney Sandberg, General Manager of AGC Biologics Colorado, expressed the significance of this achievement, stating, "This is the final piece to create a campus with comprehensive viral vector capabilities, providing developers with an end-to-end manufacturing location in North America to support everything they need for their products at every stage."

AGC Biologics' expansion aligns with its acquisition of the Longmont Campus in August 2021. The facility is staffed by scientists with over two decades of experience in handling complex cell therapy and viral vector products and materials.

The company offers global viral vector and cell therapy development, manufacturing, quality control, and regulatory services. With a strong track record, AGC Biologics supports multiple commercial viral vector products, cell therapies, and numerous cell and gene therapy clinical trials across Europe and the United States. As a Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), it operates two facilities above Grade C and leverages cutting-edge technologies to tap into the rapidly growing advanced therapeutics market.

Earlier this year, AGC Biologics introduced a formal patent platform for lentiviral and adeno-associated viral vector manufacturing, complementing its global gene and cell therapy services, ProntoLVV™ and BravoAAV™.

Report Abuse